VITAMIN C KILLS CANCER CELLS

[Guest guest]

Thu, 22 Sep 2005 09:25:47 -0500

" Orthomolecular Medicine News Service " <omns

VITAMIN C KILLS CANCER CELLS

 

 

 

 

FOR IMMEDIATE RELEASE

Orthomolecular Medicine News Service, September 22, 2005

 

Intravenous Vitamin C is Selectively Toxic to Cancer Cells

 

(OMNS) National Institutes of Health scientists have confirmed the

concepts that vitamin C is selectively toxic to cancer cells and that

tumor-toxic levels of vitamin C can be attained using intravenous

administration. The article, published in the September 12, 2005

issue of the

Proceedings of the National Academy of Sciences (1) concluded, “These

findings give plausibility to intravenous ascorbic acid in cancer

treatment.â€

 

Orthomolecular medical researchers, including Nobel laureate Linus

Pauling, have long recognized the great importance of vitamin C in

fighting cancer. (2) Scientists associated with the Bio-Communications

Research Institute (BRCI) in Wichita, Kansas have published 20 scientific

articles on the subject. (3) BCRI researchers first reported in 1995

that

vitamin C in sufficient amounts is selectively toxic to tumor cells.

The authors concluded that tumor-toxic levels of vitamin C could be

achieved only by giving the vitamin intravenously. Subsequent research

from

BCRI, published in the British Journal of Cancer in 2001 (4), was the

first to describe in detail the pharmacokinetics of high doses of

intravenous vitamin C.

 

“It is gratifying to have our research on vitamin C and cancer

confirmed by scientists at the prestigious National Institutes of

Health,â€

said Neil Riordan, Ph.D., BCRI’s Research Director. “The findings

reinforce our goal and commitment to pursue cutting edge cancer

research,†added Michael Gonzalez, Ph.D., D.Sc. of the University of

Puerto

Rico.

 

BCRI’s vitamin C research was headed by its founder Hugh D. Riordan,

M.D. The research team includes Dr. Xiaolong Meng, Dr. Joseph

Casciari, Dr. Nina Mikirova, Dr. Jie Zhong, Dr. James A. Jackson, Dr. Don

Davis, Dr. Jorge Miranda, Dr. Michael Gonzalez, Dr. Neil Riordan, and Mr.

Paul Taylor.

 

What is Orthomolecular Medicine?

 

Linus Pauling defined orthomolecular medicine as " the treatment of

disease by the provision of the optimum molecular environment, especially

the optimum concentrations of substances normally present in the human

body. " Orthomolecular medicine uses safe, effective nutritional therapy

to fight illness. For more information: http://www.orthomolecular.org

 

Take the Orthomolecular Quiz at

http://www.orthomolecular.org/quiz/index.shtml

 

The peer-reviewed Orthomolecular Medicine News Service is a non-profit

and non-commercial informational resource.

 

Editorial Review Board:

 

Abram Hoffer, M.D.

Harold D. Foster, Ph.D.

Bradford Weeks, M.D.

Carolyn Dean, M.D. N.D.

Eric Patterson, M.D.

Thomas Levy, M.D., J.D.

 

OMNS Editor: Andrew W. Saul, Ph.D. Email: omns .

BCRI contact person: Renee Olmstead: bcri

 

To at no charge: http://orthomolecular.org/.html

 

References:

 

[1] Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR,

Shacter E, Levine M. Pharmacologic ascorbic acid concentrations

selectively kill cancer cells: Action as a pro-drug to deliver hydrogen

peroxide to tissues. Proc Natl Acad Sci U S A. 2005 Sep

20;102(38):13604-9.

Epub 2005 Sep 12.

 

[2] Cameron E, Pauling L. Supplemental ascorbate in the supportive

treatment of cancer: Prolongation of survival times in terminal human

cancer. Proc Natl Acad Sci U S A. 1976 Oct;73(10):3685-9. The original

paper

is posted at

http://profiles.nlm.nih.gov/MM/B/B/K/Z/_/mmbbkz.pdf

 

Also: Cameron E, Pauling L, Leibovitz B. Ascorbic acid and cancer: a

review. Cancer Res. 1979 Mar;39(3):663-81.

 

[3] Full text papers listed and accessible at no charge at

http://brightspot.org/cresearch/index.shtml

 

[4] Casciari, J.J., Riordan NH, Schmidt, T.L., Meng, X.L., Jackson JA,

Riordan HD. Cytotoxicity of ascorbate, lipoic acid, and other

antioxidants in hollow fibre in vitro tumours. British J Cancer. 2001,

84(11),

1544-1550.

 

---------------------